For patients who develop resistance during lamivudine treatment, adefovir may be added to continued lamivudine or optionally switched to tenofovir, with no recommended switch to entecavir 1 mg/d; for patients who develop resistance during adefovir treatment, lamivudine, telbivudine or entecavir may be added or switched to tenofovir; for patients who develop resistance during entecavir treatment, the For patients who develop resistance during entecavir therapy, tenofovir or adefovir can be added; for patients who fail or develop resistance during lamivudine or tipifudine combined with adefovir, it is recommended to switch to entecavir plus tenofovir; for patients who develop resistance during lamivudine therapy, treatment can also be switched to interferon or other nucleoside analogues.